Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

2 FTSE 100 dividend stocks I’d avoid despite yielding more than 5%

These two FTSE 100 (INDEXFTSE: UKX) dividend growth stocks face uphill tasks, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 dividend yield average is a thumping 4.5%, giving savers sweet relief from terminally low savings rates.

Some of the biggest dividend stocks offer even larger yields than that, which can really turbocharge your income. Here are two 5% yielders that caught my eye. I thought they might fit nicely in your Stocks and Shares ISA but on closer inspection, I’d approach with caution.

GlaxoSmithKline

Pharmaceuticals giant GlaxoSmithKline (LSE: GSK) is one of the most renowned FTSE 100 income stocks and that remains the case today. Its current forecast yield is 5.1%, with cover of 1.4. However, the Glaxo share price has underperformed horribly, and trades 3% lower than five years ago, whereas the index as a whole is up 12% over the same period.

Worse, the dividend has been frozen at 80p since 2015, and is expected to stay there for at least the next couple of years. Free cash flow fell by 50% to £165m in the three months to 31 March. Net debt of £22bn is another worry, although plans to spin off its consumer healthcare business in a £10bn joint venture with US rival Pfizer should reduce that.  

Glaxo has been hit by some blockbuster drugs going off patent, notably Advair, which has made up almost a quarter of revenues. Investing in R&D to strengthen its drugs pipeline has taken priority over rewarding shareholders, as management looks to get those revenues flowing again.

Pipeline panic

Glaxo has had some success on that front, recently reporting positive data for several potential new medicines in HIV and oncology, but it needs a lot more of this to fully convince.

CEO Emma Walmsley is pushing on with her turnaround plans and the company’s stock is yours for a relatively bargain price of just 14.3 times forecast earnings. This is low for Glaxo and Roland Head recently suggested that this might make a good entry point.

However, you are relying on Glaxo replenishing its pipelines and there are no guarantees on that score. The stock is riskier than I feel it should be.

Sainsbury’s

Investors in supermarket giant J Sainsbury (LSE: SBRY) have endured a dismal 12 months, its stock crashing 40% in that time. The grocery sector as a whole has struggled due to Brexit, squeezed incomes, Aldi and Lidl, but the Sainsbury’s share price has had by far the worst of it. Morrisons has fallen ‘only’ 18%, and Tesco just 5%.

Sainsbury’s was hit hard by the collapse of the Asda merger, which has offset the good news from its apparently successful takeover of Argos. This is forcing the group to focus on its core retail offering, and management is now looking to cut labour costs, boost buying terms and revamp its own label range to revive profits. 

Taking stock

I reckon Sainsbury’s has its work cut out as Brexit squeezes incomes and the German discounters continue to make strides. Debt is another concern. On the plus side, the 5.5% yield is tempting and looks solid with cover of 2.0.

Sainsbury’s stock also looks cheap trading at 11.2 times earnings. Earnings may pick up slightly going forward, and the share price might spike as investors finally decide it has been oversold. I can’t work up much enthusiasm for it though.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Here’s how much passive income someone could earn maxing out their ISA allowance for 5 years

Christopher Ruane considers how someone might spend a few years building up their Stocks and Shares ISA to try and…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Was I wrong about Barclays shares, up 196%?

Our writer has watched Barclays shares nearly triple in five years, but stayed on the sidelines. Is he now ready…

Read more »

Wall Street sign in New York City
Investing Articles

Up 17% in 2025, can the S&P 500 power on into 2026?

Why has the S&P 500 done so well this year against a backdrop of multiple challenges? Our writer explains --…

Read more »

National Grid engineers at a substation
Investing Articles

National Grid shares are up 19% in 2025. Why?

National Grid shares have risen by almost a fifth this year. So much for it being a sleepy utility! Should…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

Here are the potential dividend earnings from buying 1,000 Aviva shares for the next decade

Aviva has a juicy dividend -- but what might come next? Our writer digs into what the coming decade could…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in December [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

This way, That way, The other way - pointing in different directions
Investing Articles

Is the unloved Aston Martin share price about to do a Rolls-Royce?

The Aston Martin share price has inflicted a world of pain on Harvey Jones, but he isn't giving up hope…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

How much do you need in a Stocks and Shares ISA to raise 1.7 children?

After discovering the cost of raising a child, James Beard explains why he thinks a Stocks and Shares ISA is…

Read more »